| If you are having problems viewing this message, use this link |
| |
 |
 |
Pharmalot Webcast
Shifting Ranks Among Health Care Payers & Players: You Need a Better Scorecard
June 28, 2012 at 1pm ET
Rapidly shifting market channels, Federal health reform, and change among prescription blockbusters - the US health care marketplace is more dynamic than ever. Providers and Payer organizations are forging new roles in response to global payment scenarios. The goals, methods, and influence of key purchasers in the health care value chain - self-funded insurance enterprises, municipalities, school districts - are also shifting rapidly. Are you and your colleagues keeping up with these market changes? Do you know the score? Register Now |
|
> STENTYS Starts Clinical Trial to Broaden Portfolio with New Drug-Eluting Stent
> J&J Units Submit Zytiga in U.S., EU for Use Extension
> Endo Completes Transition of Opana ER Franchise to New Formulation Designed to be Crush Resistant
> Civitas Therapeutics Initiates Phase 2a Clinical Study of CVT-301
> GSK Receives FDA Approval for MenHibrix |
| |
| Headline Sponsor |
|
Med Ad News is your source for key performance metrics and extensive analytical reporting including Top Biotechnology Companies, Top Medicines, and Top Pharmaceutical Companies. Subscribe now to SAVE 30% and access this data at PharmaLive.com plus other valuable benefits, click here. |
| Headline Sponsor |
|
| |
| Cardiovascular |
| |
STENTYS Starts Clinical Trial to Broaden Portfolio with New Drug-Eluting Stent
From the PharmaLive.com News Archive - Jun. 14, 2012
STENTYS announced it has enrolled the first patient in its 'APPOSITION IV' clinical study using its new Self-Apposing Sirolimus-eluting stent. The randomized study will enroll 150 heart attack patients who will be treated with either the STENTYS stent or Medtronic's Resolute® drug-eluting stent, and will compare stent apposition in both groups at four and nine months after treatment.
  |
| |
Investigational Ultra Long-Acting Insulin Degludec Reduced Rates of Nocturnal Hypoglycemia
From the PharmaLive.com News Archive - Jun. 11, 2012
Ultra long-acting insulin degludec, an investigational insulin being developed by Novo Nordisk, significantly reduced the rate of hypoglycemia at night in adults with type 2 diabetes while obtaining equivalent improvement in glucose control compared with insulin glargine over a 52-week period.
|
| |
| Oncology |
| |
J&J Units Submit Zytiga in U.S., EU for Use Extension
From the PharmaLive.com News Archive - Jun. 15, 2012
J&J unit Janssen-Cilag International said today it has submitted a type II variation to the EMA for prostate cancer treatment Zytiga; simultaneously, Janssen Research & Development submitted sNDA to the FDA. Both applications are intended to extend the use of Zytiga administered with prednisone.
|
| |
The MMRF Announces Collaboration with US Oncology Research for Landmark Clinical Study
From the PharmaLive.com News Archive - Jun. 13, 2012
The Multiple Myeloma Research Foundation announced an alliance with US Oncology Research to participate in the landmark CoMMpass(SM) (Relating Clinical Outcomes in MM to Personal Assessment of Genetic Profile) study sponsored by the MMRF. Seventeen US Oncology Research affiliated clinical sites will participate.
|
| |
| Pain & Inflammation |
| |
Endo Completes Transition of Opana ER Franchise to New Formulation Designed to be Crush Resistant
From the PharmaLive.com News Archive - Jun. 14, 2012
Endo Health Solutions announced the completion of the company's transition of its Opana ER franchise to the new formulation designed to be crush resistant. In connection with the completion of this transition, the FDA has moved the old formulation of Opana ER to the Orange Book Discontinued List.
|
| |
U.S. Senate Urged to Increase Federal Funding for Research into Hereditary Angioedema
From the PharmaLive.com News Archive - Jun. 12, 2012
Today, the U.S. Hereditary Angioedema Association announced it has appealed to the U.S. Senate Appropriations Committee to increase federal research funding for hereditary angioedema, a rare and potentially fatal genetic disorder. As a part of the Committee's annual "public witness testimony" hearing, which allows outside experts and stakeholders to advocate for fiscal year 2013 funding, Anthony J. Castaldo, president of the HAEA, called for the inclusion of HAE in the peer-reviewed, medical research program sponsored by the Department of Defense.
|
| |
| Central Nervous System |
| |
Civitas Therapeutics Initiates Phase 2a Clinical Study of CVT-301
From the PharmaLive.com News Archive - Jun. 15, 2012
Civitas Therapeutics announced the initiation of a Phase 2a clinical trial in Parkinson's disease patients evaluating CVT-301, an inhaled formulation of levodopa (L-dopa), for the rapid relief from motor fluctuations. CVT-301 provides immediate onset of a large and precise dose of L-dopa.
|
| |
Mountain View Pharmaceuticals Receives European Patent on Potential Long-Acting Drug for MS
From the PharmaLive.com News Archive - Jun. 11, 2012
Mountain View Pharmaceuticals announced its receipt of European Patent No. 1 667 708 B1, titled “Polyethylene Glycol Conjugates of Interferon-beta-1b with Enhanced in vitro Biological Potency.” The conjugates covered by this patent could enable less frequent and better tolerated dosing of one of the most widely used treatments worldwide for relapsing-remitting multiple sclerosis, interferon-beta-1b.
|
| |
| Infectious Disease |
| |
GSK Receives FDA Approval for MenHibrix
From the PharmaLive.com News Archive - Jun. 14, 2012
GlaxoSmithKline announced that the FDA has approved the vaccine MenHibrix [Meningococcal Groups C and Y and Haemophilus b Tetanus Toxoid Conjugate Vaccine]. MenHibrix is a vaccine indicated to prevent invasive disease caused by Neisseria meningitidis serogroups C and Y and Haemophilus influenzae type b. MenHibrix is approved for use in children aged six weeks through 18 months.
|
| |
$3M NIH Phase II SBIR Grant Awarded
From the PharmaLive.com News Archive - Jun. 13, 2012
Sanaria and the Institute for Bioscience and Biotechnology Research of the University of Maryland College Park announce the receipt of a multi-year Phase II Small Business Innovation Research (SBIR) Grant from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health.
|
|
|
|
Editor: Barbara Lempert, blempert@pharmalive.com
Advertising: Daniel Becker, daniel.becker@ubm.com,
Andrew McSherry, andrew.mcsherry@ubm.com,
Sandra Baker, sandra.baker@ubm.com
Press Releases: editorial@pharmalive.com
Technical Support: support@pharmalive.com |
Visit Our Sites:
|
| |
|
|
|
|
 |
If you feel you have received this message in error, or wish to unsubscribe from this specific product only, please REMOVE ME.
Click here to view UBM Canon's privacy policy.
UBM Canon * 300 American Metro Blvd., Suite 125, Hamilton, NJ 08619 * United States * +1-609-759-7600 |
|